https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-01-01 / Oncoimmunology 2013 Jan;2(1):e22664
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-01-01 / Oncoimmunology 2013 Jan;2(1):e226642013-01-01 00:00:002020-02-05 10:32:57Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-10-01 / Immunotherapy 2012 Oct;4(10):995-1009
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-10-01 / Immunotherapy 2012 Oct;4(10):995-10092012-10-01 00:00:002019-02-15 08:52:14Dendritic cell-based tumor vaccinations in epithelial ovarian cancer: a systematic review
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-08-21 / Hum Vaccin Immunother 2012 Sep;8(9):1179-91
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-08-21 / Hum Vaccin Immunother 2012 Sep;8(9):1179-912012-08-21 00:00:002019-02-15 08:52:22Immunotherapy in ovarian cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-05-05 / Case Rep Oncol 2012 May;5(2):212-5
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-05-05 / Case Rep Oncol 2012 May;5(2):212-52012-05-05 00:00:002019-02-15 08:48:33Successful treatment of advanced ovarian cancer with thermochemotherapy and adjuvant immune therapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-04-05 / Cancer Immunol. Immunother. 2012 Nov;61(11):1929-39
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-04-05 / Cancer Immunol. Immunother. 2012 Nov;61(11):1929-392012-04-05 00:00:002019-02-15 08:52:15Pre-clinical assessment of autologous DC-based therapy in ovarian cancer patients with progressive disease
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-02-13 / Toxicol. Sci. 2012 May;127(1):139-49
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-02-13 / Toxicol. Sci. 2012 May;127(1):139-492012-02-13 00:00:002012-02-13 00:00:00Sodium arsenite ± hyperthermia sensitizes p53-expressing human ovarian cancer cells to cisplatin by modulating platinum-DNA damage responses
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-10-22 / Cancer Immunol. Immunother. 2012 May;61(5):629-41
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-10-22 / Cancer Immunol. Immunother. 2012 May;61(5):629-412011-10-22 00:00:002019-02-15 08:52:17Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-09-17 / Cancer Immunol. Immunother. 2012 Mar;61(3):373-84
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-09-17 / Cancer Immunol. Immunother. 2012 Mar;61(3):373-842011-09-17 00:00:002019-02-15 08:52:16A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-07-01 / Immunotherapy 2011 Jul;3(7):805-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-07-01 / Immunotherapy 2011 Jul;3(7):805-72011-07-01 00:00:002019-02-15 08:52:17Combinatorial strategies for alleviation of tumor-associated immune suppression and therapeutic vaccination against ovarian cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-01-28 / Expert Opin Biol Ther 2011 Apr;11(4):441-5
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-01-28 / Expert Opin Biol Ther 2011 Apr;11(4):441-52011-01-28 00:00:002019-02-15 08:52:18Dendritic cell vaccination against ovarian cancer–tipping the Treg/TH17 balance to therapeutic advantage?
